CD7 (NCT02742727), CD19 (NCT02892695), and CD33 (NCT02944162) targeted blood cancer (455); HER2 targeted glioblastoma (NCT03383978); co-stimulating conversion receptors targeted NSCLC (NCT03656705); and MUC1 targeted multiple refractory solid tumors, including hepatocellular carcinoma, NSCLC, pancreatic tumors, and triple-negative metastatic breast tumors (NCT02839954) (455). This evidence concerns the gene MUC1 and non-small cell lung carcinoma.